Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus HISTAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus HISTAFED.
DRIXORAL vs HISTAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Category C
Category C
Antihistamine/Decongestant
Antihistamine/Decongestant Combination